Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence.
Int J Cardiol
; 324: 261-266, 2021 02 01.
Article
in English
| MEDLINE | ID: covidwho-799268
ABSTRACT
In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly evident as the final step of pro-inflammatory cytokines storm. Actually, no proven effective therapies for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection exist. Preliminary observations on anticoagulant therapy appear to be associated with better outcomes in moderate and severe COVID-19 patients with signs of coagulopathy and in those requiring mechanical ventilation. The pathophysiology underlying the prothrombotic state elicited by SARS-CoV-2 outlines possible protective mechanisms of antithrombotic therapy (in primis anticoagulants) for this viral illness. The indications for antiplatelet/anticoagulant use (prevention, prophylaxis, therapy) are guided by the clinical context and the COVID-19 severity. We provide a practical approach on antithrombotic therapy management for COVID-19 patients from a multidisciplinary point of view.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Evidence-Based Medicine
/
Fibrinolytic Agents
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Int J Cardiol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS